UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 28, 2026
ROCKET
LAB CORPORATION
(Exact
name of Registrant as Specified in Its Charter)
| Delaware |
001-39560 |
39-2182599 |
(State
or Other Jurisdiction
of
Incorporation) |
(Commission
File
Number) |
(IRS
Employer
Identification
No.) |
| |
|
|
3811
McGowen Street
Long
Beach, California |
|
90808 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
Telephone Number, Including Area Code: 714 465-5737
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instructions A.2. below):
| ☒ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| |
|
|
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
RKLB |
Nasdaq
Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement
Agreement
and Plan of Merger
On
June 28, 2026, Rocket Lab Corporation, a Delaware corporation (“Rocket Lab”), entered into an Agreement and Plan of
Merger (the “Merger Agreement”) with Iridium Communications Inc., a Delaware corporation (“Iridium”),
Ion Merger Sub I, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Rocket Lab (“Merger Sub I”)
and Ion Merger Sub II, LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Rocket Lab (“Merger
Sub II”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth therein,
Merger Sub I will merge with and into Iridium (the “First Merger”) with Iridium continuing as the surviving corporation
and an indirect wholly owned subsidiary of Rocket Lab, and immediately following the First Merger, the surviving corporation in
the First Merger will merge with and into Merger Sub II, with Merger Sub II continuing as the surviving entity (the “Subsequent
Merger” and together with the First Merger, the “Transaction”). The Transaction is generally intended to qualify
as a tax-free reorganization for U.S. federal income tax purposes so long as the value of the Stock Consideration relative to
the Cash Consideration (each as defined below) received by the holders of Iridium Common Stock (as defined below) (which could
vary depending on the price per share of Rocket Lab Common Stock (as defined below) at the First Effective Time (as defined below))
meets the conditions for tax-free treatment. Should those conditions not be met, the Subsequent Merger will not occur and the
Transaction will not qualify as a tax-free reorganization for U.S. federal income tax purposes.
Merger
Consideration
As
a result of the Transaction, at the effective time of the First Merger (the “First Effective Time”) each issued and
outstanding share of common stock of Iridium, par value $0.001 per share (“Iridium Common Stock”), other than as specified
in the Merger Agreement, will be converted into the right to receive (i) $27.00 in cash (the “Cash Consideration”)
and (ii) a number of shares (the “Stock Consideration” and, together with the Cash Consideration, the “Merger
Consideration”) of Rocket Lab’s common stock, par value $0.0001 per share (“Rocket Lab Common Stock”),
equal to the Exchange Ratio (as defined below), in each case without interest. The “Exchange Ratio” will be the following:
(i) if the Rocket Lab Common Stock Price (as defined below) is equal to or less than $67.50, then the Exchange Ratio will be 0.4000;
(ii) if the Rocket Lab Common Stock Price is greater than $67.50 but less than $112.50, then the Exchange Ratio will be the quotient
obtained by dividing $27.00 by the Rocket Lab Common Stock Price, rounded to four decimal places; and (iii) if the Rocket Lab
Common Stock Price is equal to or greater than $112.50, then the Exchange Ratio will be 0.2400. “Rocket Lab Common Stock
Price” is defined as the volume weighted average price per share of Rocket Lab Common Stock on the Nasdaq Global Select
Market for the period of the ten consecutive trading days ending on and including the second full trading day prior to the First
Effective Time.
If
the First Merger is consummated, Iridium Common Stock will be delisted from the Nasdaq Global Select Market and deregistered under
the Exchange Act, as promptly as practicable after the consummation of the First Merger.
Treatment
of Iridium Equity Awards
The
Merger Agreement provides that at the First Effective Time (i) each outstanding restricted stock unit covering Iridium Common
Stock (the “Iridium RSUs”), including any Iridium RSU that includes performance-based vesting conditions (the “Iridium
PSUs”), will be assumed by Rocket Lab and converted into a restricted stock unit award with respect to shares of Rocket
Lab Common Stock (each, an “Assumed RSU”) subject to the same terms and conditions as applied to such Iridium RSU
or Iridium PSU immediately prior to the closing of the Transaction (including the same vesting and leaver provisions), except
that such Assumed RSU will cover a whole number of shares of Rocket Lab Common Stock equal to the number of shares of Iridium
Common Stock covered by such Iridium RSU or Iridium PSU immediately prior to the First Effective Time (and, with respect to Iridium
PSUs, determined as if all applicable performance-based vesting conditions had been satisfied at target) multiplied by an Equity
Award Exchange Ratio equal to (a) the Cash Consideration divided by the Rocket Lab Common Stock Price plus (b) the Exchange Ratio
(rounded down to the nearest whole share), and each Assumed RSU will vest in full in the event of a termination of employment
without cause within 12 months following the First Effective Time (in addition to any other provisions that apply to the corresponding
Iridium RSU or Iridium PSU), and (ii) each outstanding option to purchase Iridium Common Stock (the “Iridium Options”)
and each outstanding cash-settled stock appreciation right award with respect to Iridium Common Stock (the “Iridium CSARs”)
will be fully vested and exercisable and canceled and converted into the right to receive the Merger Consideration in respect
of each share of Iridium Common Stock covered by such Iridium Option or Iridium CSAR (paid only in cash, in respect of an Iridium
CSAR), calculated net of the exercise price or strike price, as applicable, of such Iridium Option or Iridium CSAR, less applicable
withholdings.
Representations,
Warranties and Covenants
The
Merger Agreement contains customary representations, warranties and covenants made by each of Iridium and Rocket Lab, including,
among others, covenants by each of Iridium and Rocket Lab to (i) use commercially reasonable efforts to conduct its respective
businesses in the ordinary course of business during the interim period between the execution of the Merger Agreement and consummation
of the Transaction, and (ii) not engage in certain specified transactions and actions during that period. Further, unless the
Merger Agreement is validly terminated, Iridium is required to hold a meeting of its stockholders to vote upon the adoption of
the Merger Agreement and the Transaction in accordance with the terms of the Merger Agreement.
Commencing
upon the execution of the Merger Agreement, Iridium will be subject to customary “no-shop” restrictions and is not
permitted to, subject to certain exceptions set forth in the Merger Agreement,
(i) solicit, initiate or take any action to knowingly facilitate or encourage any alternative acquisition proposal or (ii) participate
in any discussions or negotiations with, furnish any material nonpublic information relating to Iridium to, or otherwise knowingly
cooperate with, any third party, relating to any alternative acquisition proposal. In addition, Iridium has agreed that, subject
to limited exceptions set forth in the Merger Agreement, the Iridium board of directors will not withdraw its recommendation to
its stockholders to vote in favor of the adoption of the Merger Agreement and the Transaction.
Conditions
to the Mergers
The
closing of the Transaction is subject to customary conditions set forth in the Merger Agreement, including (i) the adoption of
the Merger Agreement and the Transaction by the affirmative vote of the holders of a majority of the outstanding Iridium Common
Stock; (ii) the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act
of 1976 and consent of the U.S. Federal Communications Commission to the transfer of control of certain telecommunication authorizations
held by Iridium; (iii) receipt of clearances or approvals under other specified foreign investment and satellite and telecommunications
laws; (iv) the absence of any order or law issued, enforced or enacted by a governmental authority in certain specified jurisdictions
that prevents, makes illegal or enjoins the consummation of the Mergers; (v) there having not occurred a Company Material Adverse
Effect or a Parent Material Adverse Effect, each as defined in the Merger Agreement; and
(vi) the effectiveness of a registration statement on Form S-4 with respect to shares of Rocket Lab Common Stock to
be issued in the Transactions and approval of such shares for listing on the Nasdaq Global Select Market.
Termination
Either
Iridium or Rocket Lab may terminate the Merger Agreement in customary circumstances including, among others (i) the Transaction
has not been completed on or before June 28, 2027, which date may be extended to September 28, 2027 and December 28, 2027, as
applicable, pursuant to the terms of the Merger Agreement; (ii) a final order or law issued, enforced or enacted, by a governmental
authority in certain specified jurisdictions permanently prevents, makes illegal or enjoins the consummation of the Mergers; or
(iii) Iridium’s stockholders fail to adopt the Merger Agreement and the Transaction. Iridium may terminate the Merger Agreement
under certain additional circumstances, including to allow Iridium to enter into a definitive agreement for an alternative acquisition
proposal that constitutes a Superior Proposal (as defined in the Merger Agreement) subject to the terms of the Merger Agreement.
Rocket Lab may terminate the Merger Agreement under certain additional circumstances, including if Iridium’s board of directors
withdraws its recommendation to Iridium’s stockholders to vote in favor of the adoption of the Merger Agreement and the
Transaction or if Iridium materially and intentionally breaches the “no-shop”
restrictions in the Merger Agreement.
The
Merger Agreement provides for the payment of a termination fee of $223.62 million by Iridium to Rocket Lab upon termination of
the Merger Agreement under specified circumstances, including if the Merger Agreement is terminated (i) by Iridium to enter into
a definitive agreement for an alternative acquisition proposal that constitutes a Superior Proposal or (ii) by Rocket Lab because
Iridium’s board of directors withdraws its recommendation to Iridium’s stockholders to vote in favor of the adoption
of the Merger Agreement and the Transaction or because Iridium materially and intentionally breaches the “no-shop”
restrictions in the Merger Agreement. The termination fee is also payable by Iridium to Rocket Lab if the Merger Agreement
is terminated in specified circumstances and Iridium either consummates an alternative acquisition transaction or enters into
a definitive agreement providing for an alternative acquisition transaction within one year of such termination.
Financing
In
connection with the Merger Agreement, Rocket Lab entered into a commitment letter, as well as related fee letters with Deutsche
Bank Securities Inc., Wells Fargo Bank, National Association and Wells Fargo Securities, LLC and Deutsche Bank AG New York Branch,
pursuant to which Deutsche Bank AG New York Branch and Wells Fargo Bank, National Association have committed to provide, subject
to the terms and conditions thereof, a 364-day senior secured bridge term loan facility in an aggregate principal amount of $3,600.0
million.
Cautionary
Considerations
The
foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by the full text
of the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated by reference herein. The Merger Agreement
has been attached to provide investors with information regarding its terms. It is not intended to provide any factual information
about Rocket Lab or Iridium. In particular, the assertions embodied in the representations and warranties contained in the Merger
Agreement are modified or qualified by information in confidential disclosure schedules, which disclosures are not reflected in
the Merger Agreement but instead are provided by each of Rocket Lab and Iridium to the other in connection with the signing of
the Merger Agreement or in filings of the parties with the Securities
and Exchange Commission (the “SEC”). These confidential disclosure schedules
contain information that modifies, qualifies and creates exceptions to the representations and warranties and certain covenants
set forth in the Merger Agreement. Moreover, the representations and warranties in the Merger Agreement were used for the purpose
of allocating risk between Rocket Lab and Iridium rather than establishing matters as facts and were made only as of the date
of the Merger Agreement (or such other date or dates as may be specified in the Merger Agreement) and are solely for the benefit
of the parties to the Merger Agreement. Accordingly, the representations and warranties in the Merger Agreement should not be
relied on as characterization of the actual state of facts about Rocket Lab or Iridium, may no longer be true as of a given date
and may apply standards of materiality in a way that is different from what may be viewed as material to the business of Rocket
Lab or Iridium. Moreover, information concerning the subject matter of the representations and warranties may change after the
date of the Merger Agreement, which subsequent information may or may not be fully reflected in Rocket Lab’s or Iridium’s
public disclosures.
Support
Agreement
In
connection with the Merger Agreement, on June 28, 2026, each of Iridium’s directors, in their capacity as stockholders of
Iridium, entered into a Support Agreement with Rocket Lab (the “Iridium Support Agreement”) pursuant to which each
such stockholder agreed, during the term of the Iridium Support Agreement, to vote the Iridium Common Stock owned by such director
(i) in favor of adoption of the Merger Agreement, including the Transaction, (ii) against any alternative acquisition proposal,
and (iii) against any other action or agreement that is intended, or would reasonably be expected, to materially impede, interfere
with or delay the Transaction or the other transactions contemplated by the Merger Agreement. The stockholders subject to the
Iridium Support Agreement beneficially own in the aggregate approximately 1.6% of the outstanding shares of Iridium Common Stock
as of June 24, 2026. The Iridium Support Agreement terminates upon the earliest to occur of (i) the termination of the Merger
Agreement in accordance with its terms, (ii) the First Effective Time, (iii) the effectiveness of any amendment to the Merger
Agreement that decreases the amount of the Merger Consideration or that is materially adverse to Iridium’s stockholders,
(iv) with respect to each such stockholder, the termination of the Iridium Support Agreement by written agreement of each of Rocket
Lab and the applicable stockholder and (v) the Iridium board of directors withdrawing its recommendation to Iridium’s stockholders
to vote in favor of the adoption of the Merger Agreement.
The
foregoing description of the Iridium Support Agreement does not purport to be complete and is qualified in its entirety by the
full text of the Iridium Support Agreement. A form of the Iridium Support Agreement is filed as Exhibit 10.1 hereto and is incorporated
by reference herein. The Iridium Support Agreement has been attached to provide investors with information regarding its terms.
It is not intended to provide any other factual information about the stockholders party thereto. Moreover, the representations
and warranties in the Iridium Support Agreement were used for the purpose of allocating risk among the parties rather than establishing
matters of fact. Accordingly, the representations and warranties in the Iridium Support Agreement should not be relied on as characterization
of the actual state of facts about the stockholders party thereto.
The
Merger Agreement and the Iridium Support Agreement should not be read alone but should instead be read in conjunction with the
other information regarding the Merger Agreement, the Iridium Support Agreement, the Transaction, Rocket Lab, Iridium, Merger
Sub I, Merger Sub II, their respective affiliates and their respective businesses, that will be contained in, or incorporated
by reference into, the proxy statement/prospectus that Rocket Lab and Iridium will file, as well as in the Annual Reports on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings that Rocket Lab and Iridium will make with
the SEC.
Item
7.01. Regulation FD Disclosure.
On
June 29, 2026, Rocket Lab and Iridium issued a joint press release announcing execution of the Merger Agreement. A copy of the
joint press release is attached hereto and furnished herewith as Exhibit 99.1.
In
addition, on June 29, 2026, Rocket Lab and Iridium released a joint investor presentation, which includes supplemental information
about the proposed transaction. A copy of the joint investor presentation is attached hereto and furnished herewith as Exhibit
99.2.
The
information set forth under this Item 7.01, Exhibit 99.1 and Exhibit 99.2 is not being filed for purposes of Section 18 of the
Exchange Act and is not to be incorporated by reference into any filing of the registrant under the Securities Act or the Exchange
Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as
shall be expressly set forth by specific reference in such a filing.
Additional
Information and Where to Find It
This
communication is being made in respect of a proposed transaction involving Rocket Lab and Iridium. In connection with the proposed
transaction, Rocket Lab will file with the SEC a Registration Statement on Form S-4 that includes the proxy statement of Iridium
that will also constitute a prospectus of Rocket Lab. When the proxy statement/prospectus is finalized, it will be sent to the
stockholders of Iridium seeking their approval of certain transaction-related proposals. This communication is not a substitute
for the proxy statement/prospectus or any other documents which Rocket Lab or Iridium may file with the SEC in connection with
the proposed transaction.
Rocket
Lab may not sell the common stock referenced in the proxy statement/prospectus until the Registration Statement on Form S-4 filed
with the SEC becomes effective. The preliminary proxy statement/prospectus and this communication are not offers to sell any securities,
are not soliciting an offer to buy any securities in any state where the offer and sale is not permitted and are not a solicitation
of any vote or approval.
ROCKET
LAB AND IRIDIUM URGE INVESTORS AND SECURITY HOLDERS TO READ THE REGISTRATION STATEMENT ON FORM S-4, THE RELATED PROXY STATEMENT/PROSPECTUS
INCLUDED THEREIN AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Investors
and security holders will be able to obtain these materials (when they are available and filed) free of charge at the SEC’s
website, www.sec.gov. Copies of documents filed with the SEC by Rocket Lab (when they become available) may be obtained free of
charge on Rocket Lab’s website at https://investors.rocketlabcorp.com/financial-information/sec-filings or by contacting
Rocket Lab’s Investor Relations Department at investors@rocketlabusa.com. Copies of documents filed with the SEC by Iridium
(when they become available) may be obtained free of charge on Iridium’s website at https://investor.iridium.com/sec-filings
by contacting Iridium’s Investor Relations Department at investor.relations@iridium.com.
Participants
in the Solicitation
Robert
H. Niehaus, Louis M. Alterman, Thomas C. Canfield, Matthew J. Desch, Thomas J. Fitzpatrick, L. Anthony Frazier, Suzanne E. McBride,
Eric T. Olson, Kay N. Sears, Monique S. Shivanandan and Jacqueline E. Yeaney, all of whom are members of Iridium’s board
of directors, and Vincent J. O’Neill,
Iridium’s chief financial officer, may be considered participants in Iridium’s
solicitation. Information regarding such participants, including their direct or indirect interests, by security holdings or otherwise,
will be included in the proxy statement/prospectus and other relevant documents to be filed with the SEC in connection with the
transaction. Additional information about such participants is available under the captions “Proposal 1 – Election
of Directors,” “Director Compensation” and “Security Ownership of Certain Beneficial Owners and Management”
in Iridium’s definitive proxy statement in connection with its 2026 Annual
Meeting of Stockholders (the “2026 Proxy Statement”), which was filed with the SEC on April 2, 2026 (which is available
at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001418819/000141881926000022/irdm-20260402.htm), as well as on Iridium’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 12, 2026 (the
“2025 10-K”) and certain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
To the extent that holdings of Iridium’s securities have changed since the
amounts printed in the 2026 Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership
on Form 4 filed with the SEC (which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001418819).
Information regarding Iridium’s transactions with related persons is set forth
in the 2026 Proxy Statement under the caption “Transactions with Related Parties,” as well as on the 2025 10-K and
certain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Certain illustrative information regarding
the payments to that may be owed, and the circumstances in which they may be owed, by Iridium to
its named executive officers in a change of control of Iridium is set forth in the
2026 Proxy Statement under the caption “Severance and Change in Control-Related Benefits,” as well as on the 2025
10-K and certain of Iridium’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Rocket Lab may also be deemed
to be a participant in Iridium’s solicitation; information regarding Rocket
Lab will be included in the proxy statement/prospectus and other relevant documents to be filed with the SEC in connection with
the transaction. Copies of these documents may be obtained, free of charge, from the SEC or Iridium as
described in the preceding paragraph.
Cautionary
Note Regarding Forward-Looking Statements
This
communication contains “forward-looking statements” within the meaning of the federal securities laws. These forward-looking
statements are based on Rocket Lab’s and Iridium’s current expectations, estimates and projections about the expected
date of closing of the proposed transaction and the potential benefits thereof, its business and industry, management’s
beliefs and certain assumptions made by Rocket Lab and Iridium, all of which are subject to change. In this context, forward-looking
statements often address expected future events, including future business and financial performance and financial condition.
All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond
our control, and are not guarantees of future results, such as statements about the consummation of the proposed transaction and
the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject
to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied in
any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ
materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements
and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference
include, but are not limited to: (i) the completion of the proposed transaction on anticipated terms and timing, or at all, including
obtaining stockholder and regulatory approvals and satisfying other conditions to the completion of the transaction; (ii) the
occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including
the receipt by Iridium of an unsolicited proposal from a third party; (iii) failure to realize the anticipated benefits of the
proposed transaction on a timely basis or at all, including anticipated tax treatment, unforeseen liabilities, future capital
expenditures, revenues, expenses, earnings, the integration of the businesses of Rocket Lab and Iridium, synergies, economic performance,
indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion
and growth of Rocket Lab’s and Iridium’s businesses; (iv) Rocket Lab’s and Iridium’s ability to implement
their business strategies; (v) potential litigation relating to the proposed transaction that could be instituted against Rocket
Lab, Iridium or their respective directors, managers, or officers, including the effects of any outcomes related thereto; (vi)
the risk that disruptions from the proposed transaction will harm Rocket Lab’s or Iridium’s businesses, including
current plans and operations, or will otherwise divert management time from ongoing business operations on transaction-related
issues; (vii) the ability of Rocket Lab or Iridium to retain and hire key personnel; (viii) potential adverse reactions or changes
to business relationships resulting from the announcement or completion of the proposed transaction; (ix) fluctuations in, and
uncertainty as to the long-term value of, Rocket Lab or Iridium common stock (including as relating to the risk that any announcements
related to the proposed transaction could have adverse effects on the market price of such stock); (x) legislative, regulatory
and economic developments affecting Rocket Lab’s and Iridium’s businesses, including actions by government agencies
and third parties; (xi) general economic and market developments and conditions, potential changes to international trade relations,
geopolitical conflicts and effects from global pandemics, epidemics, or other public health crises; (xii) the evolving legal,
regulatory and tax regimes under which Rocket Lab and Iridium operate; (xiii) restrictions during the pendency of the proposed
transaction that may impact Rocket Lab’s or Iridium’s ability to pursue certain business opportunities or strategic
transactions; (xiv) unexpected costs, charges or expenses resulting from the proposed transaction; (xv) risks that any debt or
other financing anticipated in connection with the proposed transaction is not obtained or that such financing cannot be obtained
on the anticipated timing or terms or unexpected costs or expenses in connection therewith; and (xvi) the other risks and uncertainties,
as described in the periodic reports that Rocket Lab and Iridium file with the SEC. These risks, as well as other risks associated
with the proposed transaction, are more fully discussed in the proxy statement/prospectus to be filed with the SEC in connection
with the proposed transaction. Neither Rocket Lab nor Iridium assumes any obligation to publicly provide revisions or updates
to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances
change, except as otherwise required by securities and other applicable laws. Forward-looking statements included in this communication
are made as of the date of this communication.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits
| |
|
|
| EXHIBIT
NO. |
|
Description |
| |
|
| 2.1* |
|
Agreement and Plan of Merger, dated as of June 28, 2026, by and among Rocket Lab Corporation, Iridium Communications Inc., Ion Merger Sub I, Inc., and Ion Merger Sub II, LLC. |
| |
|
|
| 10.1 |
|
Form of Support Agreement |
| |
|
|
| 99.1
|
|
Joint Press Release, dated June 29, 2026 |
| |
|
|
| 99.2 |
|
Joint Investor Presentation, dated June 29, 2026 |
| |
|
|
| * |
Schedules have been
omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the
U.S. Securities and Exchange Commission upon request; provided, however, that the parties may request confidential treatment
pursuant to Rule 24b-2 of the Exchange Act for any document so furnished. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
|
ROCKET
LAB CORPORATION |
| |
|
|
|
| Date: June
29, 2026 |
|
By: |
/s/ Adam
Spice |
| |
|
|
Adam
Spice
Chief
Financial Officer |
| |
|
|
|
